Anavex Life Sciences (NASDAQ:AVXL) Issues Earnings Results, Beats Estimates By $0.03 EPS

Anavex Life Sciences (NASDAQ:AVXL) posted its earnings results on Wednesday. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03, Zacks reports.

Anavex Life Sciences Stock Down 0.6 %

Shares of NASDAQ:AVXL traded down $0.05 during trading on Wednesday, reaching $8.24. The stock had a trading volume of 659,999 shares, compared to its average volume of 1,579,105. The stock has a fifty day simple moving average of $9.93 and a two-hundred day simple moving average of $7.69. Anavex Life Sciences has a 52 week low of $3.25 and a 52 week high of $14.44. The firm has a market capitalization of $698.75 million, a price-to-earnings ratio of -15.93 and a beta of 0.69.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on AVXL shares. D. Boral Capital restated a “buy” rating and set a $46.00 price target on shares of Anavex Life Sciences in a report on Wednesday. HC Wainwright restated a “buy” rating and set a $42.00 target price on shares of Anavex Life Sciences in a report on Tuesday, January 28th.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.